Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: Case studies Delayed release solid dosage forms of proton pump inhibitors

Drug Development and Industrial Pharmacy

Volumn 36, Issue 2, 2010, Pages 180-189

  Missaghi, Shahrzad ^a   Young, Cara ^a   Fegely, Kurt ^a   Rajabi Siahboomi, Ali R ^a  

^a Colorcon Inc ^*  (United States)

Author keywords

Acryl EZE ; Drug layering; Enteric coat; Esomeprazole; Lansoprazole; Multiparticulates; Powder layering; Rabeprazole

Indexed keywords

ACETIC ACID; COPOLYMER; ESOMEPRAZOLE; HYDROCHLORIC ACID; LANSOPRAZOLE; POLYMETHACRYLIC ACID; RABEPRAZOLE;

ACIDITY; ALKALINITY; ARTICLE; DELAYED DRUG RELEASE; DRUG CAPSULE; DRUG COATING; DRUG DESIGN; DRUG GRANULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; DRUG SYNTHESIS; FILM COATING; HUMIDITY; IN VITRO STUDY; TABLET FORMULATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; DRUG STORAGE; EXCIPIENTS; KINETICS; OMEPRAZOLE; PROTON PUMP INHIBITORS; SOLUBILITY; TABLETS, ENTERIC-COATED;

EID: 75149114217     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903468811     Document Type: Article

References (39)

1. Porter SC, Bruno CH. (1989). Coating of pharmaceutical soliddosage forms. In: Lieberman HA, Lachman L, Schwartz J, eds. Pharmaceutical dosage forms: Tablets. New York: Marcel Dekker, 77-151.
2. Food and Drug Administration. (2009). Drugs, Dosage Form. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ FormsSubmissionRequirements/ElectronicSubmissions/Data- StandardsManualmonographs/ucm071666.htm [accessed July 6, 2009].
3. Wagner JG. (1971). Enteric coatings. In: Wagner JG, ed. Biopharmaceutics and relevant pharmacokinetics. Hamilton: Drug Intelligence Publications, 158-165
4. Guo HX. (2002). Compression behaviour and enteric film coating properties of cellulose esters. Academic dissertation, University of Helsinki, Helsinki, Finland.
5. Physician's Desk Reference (PDR). (60 ed.) (2006). Montvale: Thomson PDR.
6. Ozturk SS, Palsson BO, Donhoe B, Dressman J. (1988). Kinetics of release from enteric coated tablets. Pharm Res, 5(9):550-556
7. Deasy PB, O'Connell MJ. (1984). Correlation of surface characteristics with ease of production and in vitro release of sodium salicylate from various enteric coated microcapsules prepared by pan coating. J Microencapsul, 1(3):217-227
8. Pathak YV, Dorle AK. (1987). Study of rosin-wax combination as enteric coating material. East Pharmacist, 30:137-141
9. Pathak YV, Dorle AK. (1990). Rosin and rosin derivatives as hydrophobic matrix materials for controlled release of drugs. Drug Des Deliv, 6:223-227
10. Pathak YV, Nikore RL, Dorle AK. (1985). Study of rosin and rosin esters as coating material. Int J Pharm, 24:351-356
11. Satturwar PM, Fulzele SV, Panyamb J, Mandaogadea PM, Mundhadaa DR, Gogte BB, et al. (2004). Evaluation of new rosin derivatives for pharmaceutical coating. Int J Pharm, 270:27-36.
12. Chourasia MK, Jain SK. (2003). Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci, 6(1):33-66.
13. Missaghi S. (2006). Formulation design and fabrication of acidlabile compounds employing enteric coating technique using omeprazole as a model drug. Ph.D. Dissertation, Temple University School of Pharmacy, Philadelphia.
14. DeSesso JM, Jacobson CF. (2001). Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem Toxicol, 39:209-228
15. Ashford M, Fell JT, Attwood D, Sharma H, Woodhead PJ. (1993). An in vivo investigation into the suitability of pH dependent polymers for colonic targeting. Int J Pharm, 95:193-199 (Pubitemid 23203152)
16. Talukder R. (2004). Design and development of a rupturable drug delivery system for delivering drug to the distal gastrointestinal tract-colon. Ph.D. Dissertation, Temple University School of Pharmacy, Philadelphia.
17. Tabata T, Kashihara T, Hirai S, Kitanori N, Toguchi H. (1991). Effect of gastric pH on the absorption of a new antiulcer drug (lansoprazole) in the beagle dog. J Biopharm Sci, 2(4):319-328
18. Bodmeier R. (1997). Tableting of coated pellets. Eur J Pharm Biopharm, 43:l-8.
19. Ghebre-Sellassie I. (1994). Multiparticulate oral drug delivery. New York: Marcel Dekker.
20. Der G. (2003). An overview of proton pump inhibitors. Gastroenterol Nurs, 26(5):182-190
21. Horn J. (2000). The proton-pump inhibitors: Similarities and differences. Clin Ther, 22(3):266-280
22. Spechler SJ. (2002). Peptic ulcer disease and its complications. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger & Fordtran's Gastrointestinal and Liver Disease. Philadelphia: WB Saunders, 747-796
23. Huber R, Kohl B, Sachs G, Senn-bilfinger J, Simon W, Sturm E. (1995). The continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther, 9:363-378
24. Tutunji M, Qaisi A, El-Eswed B, Tutunji L. (2006). An in vitro investigation on acid catalyzed reactions of proton pump inhibitors in the absence of an electrophile. In J Pharm 323:110-116
25. Makino T, Tabata T, Hirai SI. (1999). Stabilized pharmaceutical composition. US patent no. 5879708.
26. Lovgren KI, Pilbrant AG, Yasumura M, Morigaki S, Oda M, Ohishi N. (1988). Pharmaceutical preparation for oral use. US patent no. 4786505.
27. Lovgren KI, Pilbrant AG, Yasumura M, Morigaki S, Oda. M, Ohishi, N. (1989). Pharmaceutical formulations of acid labile substances for oral use. US patent no. 4853230.
28. Gren T, Ringberg A, Wikberg M, Wald RJ. (2005). Controlled release bead, a method of producing the same and multiple unit formulation comprising it. US patent no. 6911217.
29. Saeki Y, Koyama N, Watanabe S, Aoki S. (1991). US patent no. 5035899.
30. Cunningham C, Fegely K. (2001). One-step aqueous enteric coating systems scale-up evaluation. Pharmaceut Tech Eur, 25(11):36-44.
31. Miner P, Katz PO, Chen Y, Sostek M. (2003). Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: A five way crossover study. Am J Gastroenterol, 98(12):2616-2620
32. Rohss K Lind T, Wilder-Smith C. (2004). Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg, and rabeprazole 20 mg in patients with gastro-oesophogeal reflux symptoms. Eur J Clin Pharmacol, 60(8):531-539 (Pubitemid 39517904)
33. Rajabi-Siahboomi AR, Farrell TP. (2008). The applications of formulated systems for the aqueous film coating of pharmaceutical oral solid dosage forms. In: McGinity JW, Felton LA, eds. Aqueous polymeric coatings for pharmaceutical dosage forms, vol.176, 3rd ed. Mountain View, CA: Informa Healthcare, 323-343
34. Rege P, Simon BH, Fegely KA, Rajabi-Siahboom AR. (2005). Investigation of a modified USP disintegration test method for enteric coated tablets. AAPS Annual Meeting and Exposition, Nashville, TN, USA, November.
35. Tabata T, Makino T, Kashihara T, Hirai S, Kitamori N, Toguchi H. (1992). Stabilization of a new antiulcer drug (lansoprazole) in the solid dosage forms. Drug Dev Ind Pharm, 18(13):1437-1447
36. Tabata T, Makino T, Kikuta J, Hirai S, Kitamori N. (1994). Manufacturing method of stable enteric granules of a new antiulcer drug (lansoprazole). Drug Dev Ind Pharm, 20(9):1661-1672
37. Makino T, Osaka JP, Tabata T, Hirai S. (1991). Stabilized pharmaceutical composition and its productions. US patent no. 5045321.
38. USP 32/NF 27. (2009). United States Pharmacopoeial Convention, Inc. Rockville.
39. Bergstrand PJA, Lovgren KI. (1998). Multiple unit tableted dosage form of omeprazole. US patent no. 5817338